Quest Diagnostics Director Gary Pfeiffer Sells $292K in Shares via 10b5-1 Plan

Executive Summary

On October 28, 2026, Quest Diagnostics Inc ($DGX) director Gary M. Pfeiffer reported an open-market sale of 1,203 shares of Common Stock executed on October 26, 2026. The transaction was completed at a flat execution price of $243.00 per share, resulting in gross proceeds of $292,329.

Transaction & Plan Specifics

• Pre-Determined Plan: The trade was conducted under a pre-established Rule 10b5-1 trading plan adopted by the insider, as noted in footnote 1.
• Holding Impact: Following the transaction, Gary Pfeiffer retains direct ownership of 29,802 shares of Quest Diagnostics common stock. The 1,203 shares sold represent approximately 3.88% of his holdings prior to the transaction.

Market & Trading Significance

This transaction carries Low market significance. Sales conducted pursuant to pre-arranged Rule 10b5-1 plans are structured systematically to reduce discretionary timing and avoid trading on material non-public information. Given the modest transaction size relative to total holdings and company market cap, the filing is characteristic of routine portfolio management and diversification rather than an operational or valuation signal.